In this article, we will take a look at 10 Strong Buy Small Cap Stocks to Invest In.
Small-cap stocks have entered a more selective phase following a strong first-half surge that collided with increasing borrowing costs and renewed investor preference for AI-linked megacaps. The Russell 2000 rose about 22% in the first half of 2026, its best start since 1991, before entering correction territory in mid-October, closing 11% lower than its August 14 record close. The pullback was obvious across the market, with Insider Monkey’s coverage of the biggest gainers and losers on October 15 showing the abrupt shift away from riskier sections of the market. The slide hasn’t erased the year’s gains, but it has pushed investors to decide between companies with long-term earnings strength and those that are simply riding the broader small-cap rally.
The fundamental backdrop remains more supportive than recent price action might suggest. Russell 2000 earnings per share increased roughly 43% in the second quarter, well ahead of projections near 26%, while roughly two-thirds of companies exceeded both revenue and earnings estimates. Janus Henderson forecasts small-cap earnings to climb 21.8% in 2027, outpacing its 10.6% estimate for large caps, while adding that the Russell 2000’s relative forward valuation remains historically attractive even after the gap with large caps narrowed.
This combination of robust earnings growth and a still-attractive relative valuation is driving investors back to smaller companies. However, increased long-term Treasury yields remain the key concern. Small caps tend to have more floating-rate or shorter-duration debt than mega-caps, and their valuations are more heavily based on earnings expected further in the future. When the 10-year Treasury yield rises, that future cash flow is discounted more heavily, reducing multiples even when operating results improve.
Royce Investment Partners said the third quarter was a temporary setback after a stellar run, though adding that the climate remains favorable for high-quality small- and micro-cap companies with strong fundamentals. The firm’s Q3 2026 Small Cap Fund letter noted that both the Russell 2000 and Russell Microcap indexes declined 7.2% during the quarter, showing how quickly opinion can shift even while company-level value stays intact.
Longleaf Partners took a similar stance in its Q3 2026 Small-Cap Fund letter, highlighting that concentrated portfolios and company-specific catalysts are more important than broad index exposure in a market where valuations and sentiment can fluctuate sharply.
For investors, that makes analyst conviction useful but insufficient. A Strong Buy rating can reveal companies where Wall Street expects meaningful upside, but small-cap coverage is thinner, projections are erratic, and a single earnings report, financing announcement, or customer loss can have a major impact. The better strategy is to combine analyst support with evidence of revenue growth, margin expansion, cash production, and a balance sheet that can withstand a higher rate environment. Investors should therefore discern between companies with a plausible route to profitability and those whose valuations are based on distant, unproven growth. That distinction is especially important in the current market, with our recent piece titled “13 Best Low Priced Growth Stocks to Invest In Right Now” highlighting why some firms are favoring small caps.
Our Methodology
We used screeners to identify stocks that are trading between $300 and $2 billion and boast a consensus ‘Strong Buy’ rating among analysts. We have also mentioned hedge fund ownership numbers for Q2 2026 to provide insight into smart money sentiments around each stock. The list is arranged according to analyst upside, with each stock carrying a minimum upside potential of 25%, signaling bullish sentiment among Wall Street analysts.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)
Share Price as of October 23: $10.20
Analyst Upside: 27.45%
Target Price: $13.00
Number of Hedge Fund Holders: 35
Xeris Biopharma Holdings, Inc. markets three specialty drugs: Recorlev for endogenous Cushing’s syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis. Second-quarter revenue increased by 29% to $92.1 million, with net product revenue up 34% and Recorlev up 81% to $56.8 million. Gross margin improved to 86% from 82% a year ago. Management adjusted full-year revenue expectations to $385 million to $390 million, implying more than 30% increase, and expects the larger Recorlev sales team to contribute more in the second half. The Phase 3 study of XP-8121 for hypothyroidism is expected to begin at the end of the year.
The costs of the expansion are obvious. Selling and administrative expenses reached $61 million in the quarter, and management expects full-year spending to increase by around $50 million from 2025. Gvoke had a sluggish start to the year before rising 8% sequentially, and numerous insiders have sold shares in recent weeks. Xeris has been working to expand the protection for its Keveyis franchise. See how that could contribute to long-term growth.
9. Astrana Health, Inc. (NASDAQ:ASTH)
Share Price as of October 23: $37.45
Analyst Upside: 39.92%
Target Price: $52.40
Number of Hedge Fund Holders: 18
Astrana Health, Inc. operates a physician-led, technology-enabled platform that assumes financial risk for patient populations through value-based contracts. The Prospect Health acquisition helped drive a 49% increase in second-quarter revenue to $972.5 million. Adjusted EBITDA increased by 43% to $68.9 million, with adjusted EPS reaching a record $0.80. Full-risk arrangements accounted for 81% of capitation revenue, up from 76% in 2025 and 35% in 2022, while general and administrative costs decreased to 5.6% of revenue from 7.7%. Management reiterated projections for revenue of $3.8 billion to $4.1 billion and raised adjusted EBITDA guidance to $255 million to $280 million from $205.4 million in 2025. First-half free cash flow of $92.9 million reduced net leverage to 2.26 times adjusted EBITDA.
Valuation remains a key aspect of the bull case. Astrana is trading at 18.91x forward earnings, a meaningful discount to its trailing P/E of 45.70x. That disparity indicates that the market is pricing in significant earnings growth as the company absorbs Prospect Health, extends full-risk arrangements, and translates scale into operating leverage.
That said, the model involves volatility. Taking full risk implies that medical costs can quickly erode margins, and second-quarter revenue reflected a one-time $15 million reduction due to CMS adjustments for the ACO REACH program. Earlier in May, Barclays raised the shares to Overweight with a $50 price target, citing an improved outlook for value-based care. Read why Barclays turned optimistic.
8. Genius Sports Limited (NYSE:GENI)
Share Price as of October 23: $6.33
Analyst Upside: 59.29%
Target Price: $10.08
Number of Hedge Fund Holders: 38
Genius Sports Limited provides leagues, sportsbooks, and media companies with official sports data, streaming, and betting technologies. After closing the Legend acquisition on April 30, it announced second-quarter revenue of $195.5 million, a 65% increase. Betting revenues grew 28% to $117.4 million, while media revenue rose 193%. Adjusted EBITDA came in at $52.6 million, with a margin of around 27%, and the company reported organic growth of more than 20% in both Genius and Legend Media on a standalone basis. It also raised full-year guidance to to $1.005 billion to $1.025 billion in revenue, with adjusted EBITDA ranging from $285 million to $295 million. A data and streaming deal with Polymarket in August sent shares up more than 14% in one day, with a prediction-market agreement with Kalshi later.
The stock is still recovering from the Legend announcement, which drove shares down to $3.92 from over $11 at the start of the year. The acquisition resulted in a GAAP net loss of $76.7 million during the quarter. The average analyst target of approximately $10 depends on integration going smoothly. See what analysts have said about the stock here.
7. Innodata Inc. (NASDAQ:INOD)
Share Price as of October 23: $59.39
Analyst Upside: 91.39%
Target Price: $113.67
Number of Hedge Fund Holders: 25
Innodata Inc. provides the training data, model evaluation, and engineering services that AI developers use to build and evaluate their systems. The company’s second-quarter revenue increased 58% to $92.1 million, marking its 12th consecutive quarter of year-over-year growth. Adjusted EBITDA increased 92% to $25.4 million, and adjusted gross margin reached 49%. Management also reaffirmed its 2026 revenue growth of 40% or more, while noting that large potential programs are not yet included.
Valuation is more demanding than headline growth indicates. Innodata is trading at 36.71x forward earnings and 45.03x trailing earnings, indicating investor optimism that AI-related demand will stay strong. That said, the premium multiple also means that the stock has less leeway for execution mistakes, especially if customer spending slows or major projects are delayed.
Concentration is the primary risk. The largest customer dropped to 37% of revenue from 56% in the first quarter, while a Big Tech customer increased to 34%, leaving two clients accounting for around 71% of sales. Revenue increased only 2% from the previous quarter. On October 22, shares closed under $60, significantly below June levels of $100 to $113, with an average analyst forecast of around $123. On the hedge fund side, Prosper Star & Stripes closed out its short position in the stock in the second quarter. You can see the detail’s in the fund’s latest investor letter.
6. Sharplink Inc. (NASDAQ:SBET)
Share Price as of October 23: $7.63
Analyst Upside: 99.21%
Target Price: $15.20
Number of Hedge Fund Holders: 21
Sharplink Inc. is one of the largest corporate holders of Ether, with 893,956 ETH as of October 19, and it uses that treasury for staking and onchain yield strategies. Revenue from staking increased to $11.5 million in the second quarter from $0.7 million the previous year, with first-half staking revenue reaching $22.7 million. On October 19, the company announced that it had activated $400 million of its ETH onchain via Ether.fi and Lido. Management’s stated goal is to increase ETH per share. Earlier in June, it raised $75 million at a premium to net asset value and repurchased 2.1 million shares at an average of around $4.70.
The accounting shows how closely linked the stock is to Ether’s price. Sharplink’s net loss in the quarter was $394.3 million, driven by a $321 million unrealized crypto loss and a $76.1 million impairment, while hedge fund ownership fell from 25 to 21. While the revenue growth exists, the shares will track Ether more than the income statement. You can read about whether staking can help to offset volatility.
5. National Energy Services Reunited Corp. (NASDAQ:NESR)
Share Price as of October 23: $20.46
Analyst Upside: 100.93%
Target Price: $41.11
Number of Hedge Fund Holders: 36
National Energy Services Reunited Corp. offers drilling, assessment, and production services to national oil companies in the Middle East and North Africa. Second-quarter revenue increased 59% to $520.8 million, adjusted EBITDA increased 51% to $106.2 million, and net income nearly tripled to $44.0 million. The Jafurah unconventional gas deal is a key driver for the company, with NESR also recently securing $300 million in five-year contracts in Kuwait. Management now considers $2 billion in revenue in 2026 to be the bare minimum, and targets a three-year revenue run rate of $3 billion.
NESR trades at 7.79x forward earnings, which is significantly lower than its trailing P/E ratio of 22.47x. That disparity reflects expectations for rapid earnings growth as the Jafurah contract ramps up, new Kuwait awards contribute, and the company approaches its $3 billion revenue run rate target.
That said, all of the company’s business sits in one region, and Iraq activity was down in the quarter due to regional interruptions. Receivables and unbilled revenue increased significantly, which should be monitored, and growth is dependent on a few large national oil company tenders. Nonetheless, the NESR’s second quarter results were undeniable, and the company made an appearance on our list of the 26 Stocks Beating Wall Street Expectations.
4. Applied Aerospace & Defense, Inc. (NYSE:AADX)
Share Price as of October 23: $10.00
Analyst Upside: 123.33%
Target Price: $22.33
Number of Hedge Fund Holders: 33
Applied Aerospace & Defense, Inc. manufactures designed subsystems for defense and space applications, such as missile and ammunition components, launch vehicle structures, and aircraft aftermarket parts. The company went public in June at $20 a share and raised approximately $635.6 million in net proceeds. Its revenue guidance for 2026 calls for $670 million to $690 million, with adjusted EBITDA ranging from $150 million to $155 million.
The shares tell a different story. Following a sector sell-off, they were trading around $11 to $12, or roughly 40% below their IPO price, while second-quarter net loss of $154 million reflected IPO-related stock compensation. That said, analyst firms are bullish, with Guggenheim naming it a top defense pick with a $30 target earlier in September, and most other. Read why Guggenheim considers it a top defense bet.
3. Mineralys Therapeutics, Inc. (NASDAQ:MLYS)
Share Price as of October 23: $20.55
Analyst Upside: 132.88%
Target Price: $47.86
Number of Hedge Fund Holders: 60
Mineralys Therapeutics, Inc. is a pre-revenue biotech whose growth case rests on one decision regarding Lorundrostat, which is expected to be ruled on by the FDA by December 22. The application followed five successful trials, and the company has formed a launch team and engaged payers who cover the majority of US lives. As of June 30, cash and investments totaled $661.4 million, enough to sustain operations through 2028, with a $500 million debt facility adding up to $400 million more on approval and commercial milestones. The company also erased its royalty obligation to Tanabe, increasing its second-quarter loss to $241.1 million.
Competition is the primary concern. AstraZeneca’s baxdrostat, known as Baxfendy, was approved in May and is already on the market, which means Mineralys will not be the first in its class. Label discussions with the FDA are planned in October and November, and the final label will determine how the drug is differentiated. Management cites its own market research, which shows a 2-to-1 physician preference over baxdrostat. Bank of America rates the stock as a Buy, with a $51 target. See why lorundrostat is gaining attention at the firm.
2. Pony AI (NASDAQ:PONY)
Share Price as of October 23: $5.14
Analyst Upside: 162.65%
Target Price: $13.50
Number of Hedge Fund Holders: 20
Pony AI is a Chinese autonomous-driving company developing robotaxi, robotruck, and autonomous-mobility technology. The company is one of the more speculative small-cap AI names on this list, but Wall Street’s conviction is notably high in comparison to its stock price. Pony AI’s valuation metrics have compressed significantly to a market cap of $2.13 billion and an EV-to-Revenue multiple of 13.94x, with a market capitalization of $2.13 billion and an EV-to-Revenue multiple of 13.94x. The company is set to announce Q3 2026 earnings on November 18, making it the next major catalyst for investors deciding whether commercialization is accelerating.
The bull case hinges on Pony AI’s position in autonomous driving as robotaxi deployment expands in China. The company’s technology platform could be worth more if it can increase the number of paid trips, reduce operating costs per vehicle and secure more city permits and partnerships. The risks are just as great. Pony AI is still in the early stages of commercialization and economics of autonomous driving are dependent on regulatory approval, fleet utilization, safety performance, capital intensity and competition from larger technology and automotive companies. The wide gap between stock price and analyst targets reflects the magnitude of the perceived opportunity and the uncertainty surrounding execution.
Insider Monkey has more on the company’s expansion strategy, including BofA’s take on Pony AI’s robotaxi expansion.
1. AEVEX Corp. (NYSE:AVEX)
Share Price as of October 23: $10.83
Analyst Upside: 167.77%
Target Price: $29.00
Number of Hedge Fund Holders: 28
AEVEX Corp. develops unmanned aerial and surface systems for the US military and its allies. The company’s second-quarter revenue nearly doubled to $201.8 million, while adjusted EBITDA rose to $28.1 million from $3.6 million, and the company turning profitable. AEVEX raised its 2026 guidance to $700 million to $720 million in revenue, with adjusted EBITDA ranging from $105 million to $111.5. That excludes BlackSea Technologies, a $650 million acquisition that closed on September 8 and one that is expected to bring around $150 million of 2026 revenue.
The shares tell a different story. Following a sector sell-off, they are trading around $11 to $12, or roughly 40% below their IPO price, while second-quarter net loss of $154 million reflected IPO-related stock compensation. That said, analyst firms are bullish, with Guggenheim naming it a top defense pick with a $30 target earlier in September, and most other. Learn why Guggenheim considers it a top defense bet here.
This is the most volatile stock on the list. Shares plunged 32% the past week to a record low of $9.64 after Bloomberg reported that the Navy had ceased ordering BlackSea’s GARC drone boat. They gained 13% the next day after AEVEX stated that no orders had been stopped and that the report was inaccurate. Guidance also predicts second-half revenue of around $291 million, compared to $418 million in the first half. Analysts are split: Oppenheimer and Jefferies rate the stock a Buy, with targets of $21 and $26, respectively, while Piper Sandler rates it Neutral at $13, citing BlackSea’s pipeline after mid-2027. We also discussed whether growth was outrunning dilution previously.
While we acknowledge the risk and potential of AVEX as an investment, we believe certain AI infrastructure stocks offer far stronger long-term potential at a much more attractive entry point. If you are looking for an AI stock more promising than AVEX that operates as a critical AI tollbooth and stands as the most important company in the world, check out our report about this must-own AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
